



*Effective treatments for
common skin disorders*

PRESS RELEASE NOVEMBER 20, 2009

MOBERG DERMA REPORTS POSITIVE PHASE II RESULTS FOR K201 AGAINST ATOPIC ECZEMA

Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in eczema patients. K201 was very well tolerated.

K201 is a topical and steroid-free treatment of mild to moderate atopic eczema which is designed to alleviate itching and reduce dryness as well as prevent bacterial- and fungal infections, without risk for development of resistance. The phase II clinical study was a comparative study where patients were treated twice daily during 4 weeks with either K201 or a moisturising pharmaceutical. The patients were evaluated both clinically and by a set of objective variables. Atopic eczema affects approximately 15-20 percent of all children and 2-3 percent of the adult population

"We are pleased with the results of the phase II study, which indicates that K201 can provide significant benefits in the treatment of atopic eczema", says Moberg Derma's CEO, Peter Wolpert.

Moberg Derma is developing a portfolio of medical products for skin disorders based on the company's patented technology as well as acquired projects. This spring the company announced its first commercial agreement and it intends to expand its existing product portfolio through in-house development as well as through further acquisitions.

Contact Moberg Derma

Peter Wolpert, CEO

Telephone: +46 8 - 522 307 00

Mobil3: +46 70 - 735 71 35

Email: peter.wolpert@mobergderma.se

Dr. Kjell Rensfeldt, Medical Director

Telephone: +46 8 - 522 307 00

Mobile: +46 70 - 712 45 32

Email: kjell.rensfeldt@mobergderma.se

About Moberg Derma

Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights for the Nordic region. The company began operations at the Karolinska Institute in 2006 and currently has 10 employees. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se